secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001601485-24-000032
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elicio Therapeutics reports Q1 2024 net loss of $11.8M; provides clinical updates for ELI-002
--------------------------------------------------------------------------------

- Net loss $11.8M ($1.15 per share) vs $8.0M in Q1 2023; R&D expense increased to $7.6M from $5.5M.
- Cash and equivalents $11.9M as of March 31, 2024, down from $12.9M at December 31, 2023.
- ELI-002 2P Phase 1 data published in Nature Medicine; ELI-002 7P Phase 1 preliminary data at ASCO in June 2024.
- Randomized Phase 2 trial of ELI-002 7P enrollment expected to complete in Q4 2024; interim analysis in Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000160148524000032/0001601485-24-000032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000160148524000032/angn-20240515.htm
  HTML page:      https://secwatch.observer/filing/0001601485-24-000032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer